menu
    • menu
    [{"orgOrder":0,"company":"TRON Group","sponsor":"Nanopharmaceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TRON Group, Inc. and Nanopharmaceutics, Inc. Announce Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"MALAYSIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Merger","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TRON Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRON Group \/ Nanopharmaceutics","highestDevelopmentStatusID":"10","companyTruncated":"TRON Group \/ Nanopharmaceutics"},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy With And Without Triapine\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanopharmaceutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanopharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanopharmaceutics \/ Not Applicable"},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Northwestern University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanopharmaceutics and Northwestern Start Phase I Study of Oral Triapine\u00ae for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanopharmaceutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanopharmaceutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Nanopharmaceutics \/ Northwestern University"}]

    Find Clinical Drug Pipeline Developments & Deals for Triapine

    Menu

    Triapine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanopharmaceutics

                            India arrow
                            Discovery on Target
                            Not Confirmed

                            Nanopharmaceutics

                            India arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Northwestern University

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nanopharmaceutics and Northwestern Start Phase I Study of Oral Triapine® for Glioblastoma

                            Details : Oral Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) in combination with temozolomide is being evaluated in the early-stage trial for recurrent glioblastoma.

                            Brand Name : Triapine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 14, 2024

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Northwestern University

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nanopharmaceutics

                            India arrow
                            Discovery on Target
                            Not Confirmed

                            Nanopharmaceutics

                            India arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Spons...

                            Details : Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer.

                            Brand Name : Triapine

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2022

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TRON Group

                            Country arrow
                            Discovery on Target
                            Not Confirmed

                            TRON Group

                            Country arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Nanopharmaceutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            TRON Group, Inc. and Nanopharmaceutics, Inc. Announce Definitive Merger Agreement

                            Details : The new company's pipeline includes 10 clinical-stage and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infe...

                            Brand Name : Triapine

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 11, 2022

                            Lead Product(s) : 3-aminopyridine-2-carboxaldehyde thiosemicarbazone,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Nanopharmaceutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth